SecBot SecBot
8-K ·Filed Nov 10, 2026

PLX

Protalix BioTherapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6d 20h ago SEC0001104659-26-124761
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Revenue growth is driven by Elfabrio sales through Chiesi, but the $25M milestone in Q1 2026 inflates year-to-date comparisons. Watch for Q4 2026 revenue to confirm whether the full-year guidance midpoint of $80.5M is achievable without additional milestones. PRX-115 Phase 2 data in H2 2027 is the next major catalyst.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

PLX drug pipeline →

PRX-115

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2
Time to market
If Phase 2 data in H2 2027 is positive, a Phase 3 program would follow, meaning potential FDA approval/commercialization is likely several years away, likely 2029-2031 at the earliest.
Next catalyst
None dated

What to watchThe next major catalyst is the Phase 2 RELEASE study (NCT07280156) topline results, expected in the second half of 2027. Positive data showing sustained uric acid reduction with infrequent dosing could significantly de-risk the program and support a path to registration. Negative or equivocal results would likely weigh heavily on the stock given PRX-115's importance as the lead pipeline asset. Interim data or updates at medical conferences in the interim could also move the stock.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$2.86
T+0 close · Nov 10, 2026 · via day close
Latest settled
+9.44%
T+1 · $3.13
Vs SPY
+8.12%
α at T+1
Next horizon
T+5
in 4h
  1. T+0 · Nov 10 $2.86entry
  2. T+1 · 6d ago +9.44%α +8.12% · $3.13
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Protalix reported Q3 2026 total revenue of $21.9M, up 22.8% YoY from $17.9M, and net income of $4.0M ($0.05 per share) versus $2.4M a year ago. The company reaffirmed its full-year 2026 revenue guidance of $78M-$83M and expects to meet or exceed it. Cash grew to $48.5M, and the PRX-115 Phase 2 trial remains on track for top-line results in H2 2027.

Key Financial Metrics

EPS
$0.05
est −$0.02 · +350.0%
Revenue
$21.9M
est $12.3M · +78.3% · +22.8% YoY
Rating
beat
Guidance
$78.0M-$83.0M
maintained
Gross Margin
64.08%

Key Facts

  • Q3 2026 total revenue was $21.9M, up from $17.9M in Q3 2025
  • Q3 2026 net income was $4.0M ($0.05 per share), up from $2.4M ($0.03 per share) in Q3 2025
  • Nine-month 2026 total revenue was $75.6M, up from $43.6M in the same period of 2025
  • Nine-month 2026 net income was $26.1M ($0.33 basic, $0.31 diluted), versus a net loss of $1.1M in the prior-year period
  • Cash, cash equivalents, and short-term bank deposits were $48.5M at September 30, 2026
  • Full-year 2026 revenue guidance reaffirmed at $78M-$83M, including a $25M milestone from Chiesi
  • PRX-115 Phase 2 RELEASE study enrollment continues; top-line results expected in H2 2027
  • Elfabrio received marketing authorization in Brazil for both every-two-weeks and every-four-weeks dosing
  • Company has no outstanding debt or warrants

Financial Impact

Q3 2026 total revenue $21.9M, net income $4.0M, cash $48.5M

revenuenet incomecash

Segment Breakdown

SegmentRevenueGrowth
Revenues from selling goods$21.8M+23.5%
Revenues from license and R&D services$91.0K-48.9%

Risk Factors

  • Revenue growth depends on continued Elfabrio penetration; any slowdown in Chiesi orders would impact results
  • PRX-115 is still in Phase 2; clinical failure or delay would remove a key pipeline value driver
  • Pfizer purchases have declined, partially offsetting Chiesi growth
  • R&D expenses are rising as the RELEASE study progresses, pressuring margins

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
80% bullish (5 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-124761
Document: plx-20261110x8k.htm0001104659-26-124761
Document: 0001104659-26-124761-index-headers.html0001104659-26-124761
Document: 0001104659-26-124761-index.html0001104659-26-124761
Document: 0001104659-26-124761.txt0001104659-26-124761
8-K Data (Synthetic)0001104659-26-124761

Track record

3 reports on PLX

Performance horizon
Filters
  1. Nov 10, 20266d ago 8-K Neutral 4/10 Viewing Entry $2.86 Now $3.03 +5.94% settles Dec 9
  2. Oct 15, 20264w ago SC 13G Neutral 3/10 Entry $2.70 to $2.96 Now $3.03 +12.22% ▲ +9.63% +11.53% vs SPY
  3. Aug 12, 202613w ago 8-K Neutral 5/10 Entry $2.62 to $2.73 Now $3.03 +15.65% ▲ +4.20% +6.10% vs SPY
Showing 3 of 3

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026